1 / 9

Non-Alcoholic Steatohepatitis (NASH): An Analysis of Recent Advances in Understanding & Management

Non-alcoholic steatohepatitis (NASH) are the fastest-growing liver diseases in the United States and the western world. Patients with NASH are at high risk for further liver damage, including fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC). No FDA-approved treatment for NASH currently exists, and physicians are limited to providing exercise and nutrition advice or attempting to recruit patients into clinical trials. Considerable opportunity exists for the development of novel agents as well as investigation of therapies currently used to treat other metabolic disorders for the treatment of NASH.

bhagyashree
Download Presentation

Non-Alcoholic Steatohepatitis (NASH): An Analysis of Recent Advances in Understanding & Management

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Non-Alcoholic SteatoHepatitis: An Analysis of Disease Prevalence, Drugs in development, Regulatory guidelines and Market opportunity in Various Geographies

  2. Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2016 The clinical trial report, “Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2016" provides an overview of Non-Alcoholic Steatohepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis. Report includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.  +1 408 520 9750  www.absolutereports.com sales@absolutereports.com

  3. Topics Revealed in this Report Top Countries Contributing to Clinical Trials in North America Top Countries Contributing to Clinical Trials in Middle East and Africa Top Five Countries Contributing to Clinical Trials in Asia-Pacific Clinical Trials by G7 Countries: Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials Clinical Trials by E7 Countries: Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials Top Companies Participating in Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials  +1 408 520 9750  www.absolutereports.com sales@absolutereports.com

  4. Major/Key players AnalysisThe Research Provides Company Overview, Business Description, SWOT Analysis, Major Products/Services, Head Office, etc. of Following Companies: GenextraS.p.a. Raptor Pharmaceutical Corp. Conatus Pharmaceuticals Inc. Galmed Pharmaceuticals Ltd. DURECT Corporation  +1 408 520 9750  www.absolutereports.com sales@absolutereports.com

  5. Scope of the Report The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months  +1 408 520 9750  www.absolutereports.com sales@absolutereports.com

  6. Why one should buy this report? Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level  +1 408 520 9750  www.absolutereports.com sales@absolutereports.com

  7. Report Details No. Of Pages : 205 No of Tables : 23 No. Figures : 24 Price : $2500 (Single User Licence)  +1 408 520 9750  www.absolutereports.com sales@absolutereports.com

  8. Related Reports: Alcoholic Hepatitis Global Clinical Trials Review, H1, 2015 http://www.absolutereports.com/alcoholic-hepatitis-global-clinical-trials-review-h1-2015-10075347 Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015 http://www.absolutereports.com/non-alcoholic-fatty-liver-disease-nafld-global-clinical-trials-review-h1-2015-10075371  +1 408 520 9750  www.absolutereports.com sales@absolutereports.com

  9. Contact: Mr. AmeyaPingaley  +1 408 520 9750  www.absolutereports.com sales@absolutereports.com

More Related